Navigation Links
Pharmaceutical Internal Communications Function Morphs to Address Corporate Priorities
Date:7/22/2011

CHAPEL HILL, N.C., July 22, 2011 /PRNewswire/ -- The structure of a biopharmaceutical company's Internal Communications group must evolve to reflect the changing goals and strategies. Realigning to support new corporate initiatives and establishing service levels to reflect priorities and resources are key improvement areas for Internal Communications executives in 2012.

"Differentiated services hold great value during times of resource reductions," according to "Internal Communications Excellence: Optimizing Group Structure & Operations," primary research conducted by Best Practices, LLC.

Download a complimentary white paper at http://www3.best-in-class.com/rr1094.htm that includes selected best practices drawn from extensive primary research with executives from 26 leading biopharmaceutical and medical device companies. The full 61-page report contains more than 100 benchmark metrics and 20 executive narratives, providing communications executives with organizational models and trends and insights about structure, staffing and investment levels.

Key insights include:

  • In the Pharma Segment, 52 percent of Internal Communications executives noted their group has a business unit focus while 48 percent have an enterprise-wide focus. Only 14 percent noted a product focus for the Internal Communications group.
  • While a majority of both biopharma and other industries favor a centralized approach for Internal Communications, a third of both takes a regional approach, where staff are placed in major regional offices (although a central group still resides at headquarters).

In conjunction with this study, "External Communications Excellence: Optimizing Group Structure & Operations," primary research conducted by Best Practices, LLC, addresses current trends in external communications with respect to its structural models, staffing and investment levels. A complimentary except is available at http://www3.best-in-class.com/rr1095.htm.

For more information on this study and other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.  

BEST PRACTICES, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 out of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... CAMBRIDGE, Mass. , March 23, 2017 ... the enrollment of its first patient in a Phase ... an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane ... suggest is overexpressed in 50-100% of many major tumor ... cancers. "The initiation of this study is ...
(Date:3/23/2017)... March 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" ... specialty pharmaceutical company, is pleased to announce that ... approval from the U.S. Food and Drug Administration ... ("ANDA") for tetrabenazine tablets in the 12.5 mg ... is a generic equivalent of the branded product ...
(Date:3/23/2017)...   Casetabs , the pioneer surgery coordination application, ... the iPhone. With this new release, Casetabs is further ... physician offices, ambulatory surgery centers (ASCs) and hospitals. The ... even faster, more reliable access to case information. ... connect care teams so that surgeries can be coordinated ...
Breaking Medicine Technology:
(Date:3/23/2017)... Raleigh, NC (PRWEB) , ... March 23, 2017 , ... ... the ride). Life is serious so build on a solid foundation. As experts ... high priority vital information that is coming soon. Inflownomics deliver ripe, fresh, clean & ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams & ... This competition was hosted jointly by HSN and Good Housekeeping. , Steven ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... software solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 ... coding audit process for all medical chart types with a comprehensive set of ...
(Date:3/23/2017)... , ... March 23, 2017 , ... “My Journey Through ... experience with an infinitely more profound faith of God’s promise of Heaven for His ... Jr., who spends each day with his wife, three children and six grandchildren living ...
(Date:3/23/2017)... ... , ... “More Corruption”: a simple and strong explanation of the God’s love. “More Corruption” ... Heaven was asked by God to write a book about Him. , She says, “I’m ... kept my commitment to the Lord God. They have not walked in my shoes and ...
Breaking Medicine News(10 mins):